Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck writes off hepatitis C drug

by Ann M. Thayer
March 6, 2017 | A version of this story appeared in Volume 95, Issue 10

Merck & Co. has decided to write off its R&D program for uprifosbuvir, a nucleotide prodrug in Phase II development for treating hepatitis C. Merck acquired the compound when it purchased Idenix Pharmaceuticals for $3.9 billion in 2014. Recent changes in the pricing and sales outlook for the competitive hepatitis C market caused Merck to reassess its prospects and the drug’s value. As a result, the company will take a $2.9 billion pretax charge against 2016 earnings. Merck says it will continue to evaluate options for the uprifosbuvir clinical development program.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.